Phase II trials of interferons-alpha and -beta in advanced sarcomas.

Interferons (IFNs)-alpha and -beta were administered to patients with metastatic sarcomas in two different Eastern Cooperative Oncology Group studies. In one study, patients received IFN-alpha 2b, 20 million units/m2 i.v. 5 days/week x 4, then 10 million units s.c.t.i.w. In the second study, patients received IFN-beta ser 180 million units t.i.w. Of 87 patients evaluable for response, there were three responses in 64 patients (5%) treated with IFN-alpha-2b and no responses in 23 patients treated with IFN-beta ser. Severe or life-threatening fatigue with decline in performance status complicated treatment of 37% of patients receiving IFN-alpha 2b and 17% of patients receiving IFN-beta ser. Further investigation of IFNs in sarcomas should depend on evidence from preclinical studies demonstrating synergistic effects of IFNs combined with a cytoreductive modality which has proven activity in these malignancies.
AuthorsE C Borden, K Kim, L Ryan, R H Blum, M Shiraki, D C Tormey, R L Comis, R G Hahn, D R Parkinson
JournalJournal of interferon research (J Interferon Res) Vol. 12 Issue 6 Pg. 455-8 (Dec 1992) ISSN: 0197-8357 [Print] UNITED STATES
PMID1289413 (Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Interferon-alpha
  • Recombinant Proteins
  • Interferon beta-1b
  • Interferon-beta
  • interferon alfa-2b
  • Interferon beta-1a
  • Adult
  • Aged
  • Drug Administration Schedule
  • Female
  • Humans
  • Infusions, Intravenous
  • Injections, Subcutaneous
  • Interferon beta-1a
  • Interferon beta-1b
  • Interferon-alpha (therapeutic use)
  • Interferon-beta (therapeutic use)
  • Male
  • Middle Aged
  • Recombinant Proteins
  • Sarcoma (secondary, therapy)
  • Soft Tissue Neoplasms (therapy)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: